Publication
Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
Vanessa E Kennedy, Cheryl A C Peretz, Anushka Walia, Brenda Chyla, Yan Sun, Jason Hill, Elaine Tran, Andrew D Koh, Timothy Ferng, Samantha Pintar, Matthew F Jones, Bogdan Popescu, Isabelle Lomeli, Farid Chehab, Natalia Murad, August John, Ritu Roy, Adam Olshen, Christine A Berryhill, Christopher Davis, Steven P Angus, Jose M Rivera, Alicia Meshulam, Elliot Stieglitz, Sunil Joshi, Elie Traer, Monique Dail, Habib Hamidi, Jessica K Altman, Naval Daver, Mark Levis, James McCloskey, Alexander E Perl, Catherine C Smith
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Bulk sequencing of relapsed tumors reveals mutations associated with resistance to cancer therapy but is insufficient to fully assess all causes of relapse. Because of inherent tumor heterogeneity, on-treatment tumor evolution may select genetically distinct clones or shifts in malignant…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT03625505registry_reference1.00
Registered trialsNCT03625505
Curated evidence
Evidence citing this paper (0)
Data not yet available